SEP 06, 2018 11:00 PM PDT

First FDA Approved Drug Derived From Marijuana Used to Treat Two Rare Forms of Epilepsy

WRITTEN BY: Amanda Kahl

The FDA (Food and Drug Administration) approved the first oral cannabidiol solution called Epidiolex in June of 2018. This medicine was approved as a treatment for two forms of severe drug-resistant epilepsy. This is the first time that the federal government has approved a medication derived directly from the cannabis plant. 

LGS (Lennox-Gastaut Syndrome) and DS (Dravet Syndrome) are two rare and severe forms of epilepsy with onset in early childhood. "The syndromes are categorized as developmental and epileptic encephalopathies, in which the epileptic activity is thought to contribute to developmental delay and behavioral abnormalities beyond the pathology of the underlying disease," stated Teresa Buracchio, who is the Clinical Team Leader from the Division of Neurology Products at the FDA. These forms of refractory epilepsy syndromes are resistant to drugs that are typically used for the treatment of seizures. Buracchio further explains that "Both syndromes are associated with higher rates of mortality than in the general epilepsy population, primarily due to status epilepticus and sudden unexpected death in epilepsy patients." 

The FDA conducted three randomized, double-blind, placebo-controlled trials with patients who have LGS and DS. The results from the study performed with 225 patients with LGS showed significant improvement with the use of CBD, "The median number of "drop seizures" (which can cause falls) during a 28-day period fell from 85.5 to 44.9 in the high-dose group (a decrease of 49 percent), from 86.9 to 50 in the low-dose group (43 percent), and from 80.3 to 72.7 in the placebo group (21 percent)." In the study that was performed with 120 patients with DS also showed significant improvement with the use of CBD, "The median number of convulsive seizures over 28 days fell from 12.4 to 5.9 in the CBD group (a drop of 52 percent) and from 14.9 to 14.1 in the placebo group (5 percent)."

Epidiolex contains CBD, which is a cannabinoid found within the marijuana plant. It is known that cannabinoids interact with a multitude of neurotransmitters and neuromodulator systems and have the ability to interact with cellular pathways. By acting as ligands, they are able to modulate a receptor's behavior and their downstream biological pathways. According to GW Pharmaceuticals (the company that created the drug), CBD produces an anticonvulsant effect, it does this by, "...modulating a number of endogenous systems including, but not limited to neuronal inhibition (synaptic and extrasynaptic GABA channels, modulation of intracellular calcium (TRPV, VDAC, GPR55), and possible anti-inflammatory effects."

Both forms of seizures are difficult to control and with the treatment option of CBD for patients diagnosed it can dramatically improve their quality of life. The use of medical marijuana is approved in 30 states and Washington D.C., 25 out of these 30 states specifically recognize epilepsy as a qualifying condition. These states allow treatment of epilepsy with low dose THC or high dose CBD oil and are now making it easier to legally obtain the drug Epidiolex. The creation of this drug and its approval are a huge step in offering patients a safe, controlled, and tested medication. 

Sources: ReasonFDA Briefing DocumentGWPharm Mechanism of Action

About the Author
  • Amanda has a Bachelor's in Biological Sciences from the University of Cincinnati. She has a passion for animals, conservation, and environmental sciences. Through her career in science and research, she is able to develop her passion and hopes to pass on to others the joy of learning about science.
You May Also Like
JUL 08, 2021
Health & Medicine
Cannabinoid Hyperemesis Syndrome Is Helped by Hot Pepper Cream
JUL 08, 2021
Cannabinoid Hyperemesis Syndrome Is Helped by Hot Pepper Cream
A new research review suggests that capsaicin cream, rubbed into the abdomen, may help with the symptoms of cannabinoid ...
AUG 12, 2021
Cannabis Sciences
Medicinal Cannabis May Help with Stuttering
AUG 12, 2021
Medicinal Cannabis May Help with Stuttering
Medicinal cannabis reduced treatment-resistant stuttering in a 20-year-old male patient. The case study was published in ...
SEP 09, 2021
Health & Medicine
Cannabis and Pain Management- A Double Edged Sword?
SEP 09, 2021
Cannabis and Pain Management- A Double Edged Sword?
In 2016 it was estimated by the CDC that 20.4% of Americans have chronic pain. Chronic pain is a primary reaso ...
OCT 25, 2021
Health & Medicine
Latest Cannabis Extraction Developments
OCT 25, 2021
Latest Cannabis Extraction Developments
In response to the growing demand for concentrates, cannabis product manufacturers are exploring new technological advan ...
OCT 29, 2021
Cannabis Sciences
Hempcrete's Role in Energy Efficient Building Materials
OCT 29, 2021
Hempcrete's Role in Energy Efficient Building Materials
As more people explore the potential of hemp building materials, research studies are focusing on hempcrete performance ...
DEC 09, 2021
Cannabis Sciences
Considering Cannabinoids as a COVID-19 Treatment
DEC 09, 2021
Considering Cannabinoids as a COVID-19 Treatment
Research suggests that Cannabis sativa-derived cannabinoids – such as cannabidiol (CBD), Δ9tetrahydrocannabi ...
Loading Comments...